Category: Article
Authors: Antonio Ortiz-Mena & Christopher G. Sheeron
Source: AOM Advisors / Action for Health

The United States is at a pivotal moment in medical device trade policy. The authors argue that Medical devices warrant a differentiated rather than uniform Section 232 response. Also, the affordability consequences of Section 232 tariffs in this sector are real, proximate, and asymmetrically distributed. Finally, that origin differentiation is essential to a legally durable and strategically coherent Section 232 framework.